T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines

Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara ProSaurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Original languageEnglish (US)
Pages (from-to)1460-1467
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number11
DOIs
StatePublished - Nov 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this